Provided by Tiger Trade Technology Pte. Ltd.

crane

206.13
-2.2850-1.10%
Volume:209.13K
Turnover:43.46M
Market Cap:11.87B
PE:35.98
High:212.69
Open:210.64
Low:206.13
Close:208.41
52wk High:230.50
52wk Low:159.58
Shares:57.60M
Float Shares:48.76M
Volume Ratio:0.59
T/O Rate:0.43%
Dividend:0.98
Dividend Rate:0.48%
EPS(TTM):5.73
EPS(LYR):6.26
ROE:16.52%
ROA:12.73%
PB:5.45
PE(LYR):32.95

Loading ...

Crane Co Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 29

GUIDANCE: (CR) Crane Expects Full Year 2026 Adjusted EPS Range $6.85 - $7.05, vs. FactSet Est of $6.85

MT Newswires Live
·
Jul 29

Crane Q2 FY26 EPS Rises 19% to $1.63; Net Sales Increase 25.6% to $724.7 Million

Reuters
·
Jul 29

Crane Company Q2 Sales Rise 26%, Beat Estimates; Outlook Raised

Reuters
·
Jul 29

Crane reports Q2 adjusted EPS $1.79, consensus $1.67

TIPRANKS
·
Jul 29

Crane Company Q2 Sales USD 724.7 Million Vs. IBES Estimate USD 706.2 Million

Reuters
·
Jul 29

Crane Holdings Q2 Adj. EPS $1.63 Misses $1.67 Estimate, Sales $724.700M Beat $706.178M Estimate

Benzinga Earnings
·
Jul 29

Crane Co Fy2026 Shr View $6.82

THOMSON REUTERS
·
Jul 29

Crane Company Outlook FY Adjusted EPS USD 6.85-7.05 VS. Ibes Estimate USD 6.82

THOMSON REUTERS
·
Jul 29

Crane Company Reports Second Quarter 2026 Results and Raises Full Year Adjusted EPS Guidance

THOMSON REUTERS
·
Jul 29

U.S. Earnings Preview: After Market Close July 28

Dow Jones
·
Jul 29

Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Dow Jones
·
Jul 28

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 27

Press Release: Standard Biotools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction

Dow Jones
·
Jul 20

Crane (CR) Acquires PSI, Is The Stock Near Fair Value?

Simply Wall St.
·
Jul 20

Analysts Offer Insights on Industrial Goods Companies: ABB Ltd (OtherABBNY) and Crane Company (CR)

TIPRANKS
·
Jul 20

InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL

GlobeNewswire
·
Jul 14

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

GlobeNewswire
·
Jul 07

Crane (CR) Leaves Russell Defensive Indexes, Is The Premium Already Priced In?

Simply Wall St.
·
Jul 06

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

GlobeNewswire
·
Jun 30